Exponent Inc filings document operating results, Regulation FD disclosures, capital-return actions, and governance matters for a science and engineering consulting company. Recent Form 8-K reports record quarterly financial results, dividend declarations, and share repurchase authorizations tied to the company’s common stock.
Proxy materials cover shareholder voting matters, director elections, executive compensation, pay-versus-performance tables, and board governance. The filing record also includes material-event disclosures related to leadership and corporate governance, along with capital-structure disclosures relevant to Exponent’s public-company reporting.
Exponent, Inc. (EXPO) reported third-quarter 2026 revenue of $173.7 million, up 18% from a year earlier, while revenue before reimbursements rose 12% to $153.1 million. Net income was $30.9 million, or $0.64 per diluted share, compared with $28.0 million, or $0.55, in the prior-year quarter. EBITDA, a non-GAAP measure, was $45.0 million, equal to 29.4% of revenue before reimbursements, versus $38.8 million and 28.3% a year earlier.
For fiscal 2026, Exponent raised its outlook to 10%–11% growth in revenue before reimbursements and EBITDA of 28.0%–28.3% of that revenue; fourth-quarter outlook is 8%–10% growth and EBITDA of 26.3%–26.8%. Through the first three quarters, it paid $46.1 million in dividends, repurchased $146.1 million of common stock, and had $114.7 million in cash and cash equivalents as of October 2, 2026. The board declared a $0.31-per-share quarterly cash dividend payable December 18, 2026, to holders of record December 4, 2026; future declarations and dates are subject to final board determination.
EXPONENT INC (EXPO) reports that Group Vice President Shukri Jeries Souri purchased 184 shares of common stock on September 18, 2026 at $68.4452 per share, increasing directly held shares to 40,873. The purchase represents whole shares acquired under the company’s Dividend Reinvestment Plan, which also added fractional shares.
EXPONENT INC (EXPO) reported the initial equity holdings of Group Vice President Souri Shukri Jeries on a Form 3. The filing shows direct ownership of 40,689 shares of Common Stock and several grants of Restricted Stock Units that are each convertible into Common Stock on a 1-for-1 basis.
The Restricted Stock Units reference underlying Common Stock of 1,600 shares expiring March 10, 2027, 5,558 shares expiring March 15, 2028, 1,936 shares expiring March 14, 2029, and 8,016 shares expiring March 13, 2030, all held directly.
EXPONENT INC (EXPO) reported insider equity transactions by Chief Executive Officer Catherine Corrigan. On 2026-08-17 she exercised 2,379 Non-Qualified Stock Options at an exercise price of $29.05 per share, receiving an equal number of common shares and fully using that option grant. On the same date she sold 1,707 common shares at $66.2776 per share in a transaction the company identifies as made under a Rule 10b5-1 trading plan, with the sale described as covering the option exercise price and related taxes.
Exponent, Inc. (EXPO) reports a planned sale of 1,707 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, related to an exercise of stock options on 08/17/2026. The filing also lists prior Rule 10b5-1 sales by Catherine Corrigan over the preceding three months.
Those prior transactions involved 1,737 shares on 07/15/2026 for $109,044.69 and 4,119 shares on 06/15/2026 for $235,303.23, all in Exponent common stock.
Exponent, Inc. delivered strong Q2 2026 results, with total revenues rising to $171.6 million from $141.9 million and revenues before reimbursements increasing to $148.9 million. Growth was driven mainly by the Engineering and Other Scientific segment and AI-related user research studies, including one large study equal to about 4% of net revenues. Net income grew to $29.4 million, diluted EPS to $0.60 from $0.52, and EBITDA to $42.7 million, or 28.7% of revenues before reimbursements.
For the first half of 2026, revenues reached $337.9 million and net income $59.0 million, with diluted EPS of $1.19. Operating cash flow was $29.9 million, while cash and equivalents fell to $66.6 million from $221.9 million, primarily due to increased share repurchases. The company spent $146.1 million buying back stock in six months, including 1.125 million shares in Q2 at an average $59.88, and declared cash dividends of $0.62 per share year to date. After quarter-end, the board approved another $0.31 dividend and authorized an additional $50 million share repurchase program.
Exponent Inc. reports that Chief Executive Officer Catherine Corrigan exercised options to acquire 12,665 shares of common stock on July 28, 2026 at an exercise price of $37.45 per share, converting a Non-Qualified Stock Option scheduled to expire on February 15, 2028.
Following the exercise, Corrigan directly holds 128,436 shares of Exponent common stock.
Exponent, Inc. reported strong results for the second quarter ended July 3, 2026, with total revenues rising 21% to $171.6 million and revenues before reimbursements up 12% to $148.9 million versus a year earlier. Net income was $29.4 million, or $0.60 per diluted share, and EBITDA increased to $42.7 million, representing a 28.7% margin on revenues before reimbursements. Growth was broad-based, led by engineering and other scientific services and supported by higher demand in AI-enabled product user research, utilities risk management, and dispute-related work.
For the first half of 2026, total revenues grew to $337.9 million and net income to $59.0 million, while EBITDA reached $85.9 million, or 28.6% of revenues before reimbursements. The company paid $31.3 million in dividends, repurchased $146.1 million of stock, and ended the period with $66.6 million in cash and cash equivalents. Management raised full‑year 2026 guidance, now expecting revenues before reimbursements to grow 9%–10% and EBITDA margin of 27.8%–28.1%. The board declared a quarterly dividend of $0.31 per share payable September 18, 2026 and increased the share repurchase authorization by $50 million.
Exponent Inc. reported that CEO Catherine Corrigan exercised non-qualified stock options for 2,379 shares of common stock at $29.05 per share and on the same date sold 1,737 shares at $62.7776 per share to cover the option exercise price and taxes. After these trades, she directly held 115,771 common shares, and the transactions were effected under a Rule 10b5-1 trading plan.
Catherine Corrigan has filed a notice of proposed sale for 1,737 shares of EXPO common stock, expected on 07/15/2026 through Morgan Stanley Smith Barney LLC Executive Financial Services. The shares are shown as acquired that day via cash exercise of stock options. The notice also lists 10b5-1 sales of 4,119 and 4,194 EXPO shares on 06/15/2026 and 05/15/2026, with stated values of $235,303.23 and $226,725.54, respectively.